Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd is a pharmaceutical company that generates revenue primarily through the sale of prescription and over-the-counter medications.
Business. Jenburkt Pharmaceuticals Ltd (JENA.BO) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in India and is primarily listed on the Bombay Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data. Consequently, the company is described at the industry level within the broader pharmaceuticals sector.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Jenburkt Pharmaceuticals Ltd (JENA.BO) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in India and is primarily listed on the Bombay Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data. Consequently, the company is described at the industry level within the broader pharmaceuticals sector.
Jenburkt Pharmaceuticals Ltd has a capital structure with 4,413,300 basic and diluted shares outstanding, indicating no dilution from potential share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company reported a net income of INR 74,160,000 for the period, with an operating income of INR 87,704,000. Gross profit stood at INR 262,457,000, representing a strong margin performance. These figures suggest a healthy profitability profile, though direct comparisons to industry medians are not available in the current dataset.
Geographic and segment exposure data are not disclosed in the available financials, making it difficult to assess revenue concentration or segment-specific performance. The company operates as a single entity without disclosed business segments.
Growth trajectory data is limited, as no outlook figures or revenue history beyond the latest period are available. Analysts have provided a mean price target of INR 1,370.00, with a single "buy" recommendation and no "strong buy" or "hold" ratings.
Risk factors include the inability to assess liquidity risk and the absence of detailed risk disclosures in source documents. Dilution risk is currently low, with no evidence of recent or planned share issuance.
No recent events, such as filings or transcripts, are available in the source documents to provide additional context on the company's operations or strategic direction.
- Jenburkt Pharmaceuticals Ltd has a strong profitability profile with a net income of INR 74,160,000 and a gross profit of INR 262,457,000.
- The company has no dilution from share issuance, with basic and diluted shares outstanding being equal.
- Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
- Analysts have provided a mean price target of INR 1,370.00, with a single "buy" recommendation.
- No recent events or detailed risk disclosures are available in the source documents.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue INR 1.42B, +3,8% YoY; Operating income +9,5% YoY.
- ▍Revenue INR 1.42B, +3,8% YoY
- ▍Operating income +9,5% YoY
- ▍Net income +5,6% YoY
- ▍Free cash flow +0,9% YoY
- ▍Net margin 18.3%
Revenue INR 1.37B, +10,3% YoY; Operating income +10,8% YoY.
- ▍Revenue INR 1.37B, +10,3% YoY
- ▍Operating income +10,8% YoY
- ▍Net income +10,4% YoY
- ▍Free cash flow +17,0% YoY
- ▍Net margin 18.0%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Jenburkt Pharmaceuticals Ltd Market data — financials · 2026-05-28
- Jenburkt Pharmaceuticals Ltd Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,01 %$0M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Debt-to-equity (FY 2025-12-31): -1.09xDerived (calculated)
- Current ratio (FY 2025-12-31): 42.56xDerived (calculated)
- Current assets (annual): USD 1.07MSEC XBRL filing
- Total assets (annual): USD 236.57MSEC XBRL filing
- Total liabilities (annual): USD 13.83MSEC XBRL filing
- Current liabilities (annual): USD 25.03KSEC XBRL filing
- Shareholders' equity (annual): USD -12.7MSEC XBRL filing